SCHEMBL15034149

SCHEMBL15034149

CC1(C)CN(C(=O)c2cccc(S(C)(=O)=O)c2)CCN1C(=O)c1ncn(-c2ccccc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
CTSG P08311 1/20 0.39
CMA1 P23946 1/20 0.39
CASP6 P55212 1/20 0.39
CASP8 Q14790 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CFTR P13569 1/20 0.38
TSHR P16473 4/20 0.38
LMNA P02545 3/20 0.38
MAPK1 P28482 2/20 0.38
MAPT P10636 5/20 0.37
PKM P14618 1/20 0.37
USP2 O75604 2/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034134 0.88 CFTR (0.44) SMN1; SMN2POLBCFTRTSHRMAPT
SCHEMBL15034138 0.87 HPGD (0.44) SMN1; SMN2POLBHTTL3MBTL1CFTR
SCHEMBL15034147 0.86 HPGD (0.41) SMN1; SMN2POLBHTTCFTRTSHR
SCHEMBL15034131 0.86 CYP3A4 (0.48) SMN1; SMN2HTTTSHRMAPK1USP2
SCHEMBL15020006 0.86 ALDH1A1 (0.44) SMN1; SMN2POLBHTTL3MBTL1MAPT
SCHEMBL15034119 0.86 POLB (0.44) SMN1; SMN2POLBLMNAUSP2ALDH1A1
SCHEMBL15034139 0.85 ALDH1A1 (0.47) SMN1; SMN2POLBL3MBTL1CFTRMAPT
SCHEMBL15020047 0.85 HPGD (0.41) SMN1; SMN2POLBCFTRTSHRLMNA
SCHEMBL15034152 0.84 MAPT (0.39) SMN1; SMN2POLBCFTRTSHRLMNA
SCHEMBL15034153 0.84 ALDH1A1 (0.39) SMN1; SMN2POLBCFTRTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 SMN1; SMN2 2592/4885POLB 4052/4885HTT 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.